Cancer

Personalis Receives Medicare Coverage for NeXT Personal in Lung Cancer Surveillance

The NeXT Personal molecular residual disease test can now be used for surveillance of patients with Stage I to III non-small cell lung cancer.

Cancer

Valley Diagnostics Licenses Biomarker Technology for Cancer, Disease Detection

Valley Diagnostics has secured exclusive global rights to develop point-of-care lateral flow tests for prostate cancer, lung cancer, and animal diseases, with product rollout planned for 2026.

Cancer

BillionToOne Partners with Epic to Integrate Prenatal, Oncology Tests into EHR

BillionToOne has partnered with Epic to integrate its UNITY Complete prenatal and Northstar oncology tests into Epic’s EHR system, enabling direct ordering and results delivery for healthcare providers.

Human Longevity Expands $1M Cancer Pledge to Include Colon Cancer

Dec 31, 2025 | Colorectal

The biotechnology company’s integrated screening approach combines whole-genome sequencing, imaging, and multiple biomarker tests to enable early detection.

PreciseDx Presents Validation Data for AI Breast Cancer Recurrence Test

Dec 29, 2025 | Breast

Three abstracts showcase PreciseBreast’s ability to predict recurrence risk in early-stage invasive breast cancer using digital pathology.

Why Cervical Cancer Screening Rates Are Falling—and What Could Help Reverse the Trend

Dec 24, 2025 | Cervical (HPV)

Despite effective prevention tools, Millennials are delaying screening. New approaches may help remove barriers to participation.

AI Pathology Solution Shows Concordance with Pathologists in HER2 Interpretation for Biliary Tract Cancer

Dec 23, 2025 | Cancer

Study in biliary tract cancer finds the solution achieved 83.5% overall concordance rate with expert interpretations.

CTC Counts Show Value in Guiding Metastatic Breast Cancer Treatment Decisions

Dec 22, 2025 | Breast

Researchers found that circulating tumor cell counts stratified patients by disease aggressiveness and were associated with differing outcomes following endocrine versus combination therapy.

Genomic Test Shows Promise for Identifying High-Risk Prostate Cancer in African American Men

Dec 22, 2025 | Prostate

A genomic test widely used in prostate cancer care can more accurately identify which men with early-stage disease face high risk of recurrence after treatment.

Reducing the Cost of Cancer Care with Improved Diagnostics

Dec 22, 2025 | Cancer

Better cancer testing can help patients avoid unnecessary scans and biopsies, while also lowering costs for the healthcare system.

Yenos Analytical Launches Multi-Cancer Early Detection Urine Test

Dec 19, 2025 | Cancer, Company News, Molecular Diagnostics

The direct-to-consumer laboratory-developed test detects six cancer types with 97% sensitivity and specificity using microRNA biomarkers, according to the company.

Blood Test Shows Chemotherapy Response in Glioblastoma After First Treatment Dose

Dec 18, 2025 | Cancer, Diagnostic Technologies, Hematology & Serology

New diagnostic chip pulls packets released from tumor cells out of blood, showing whether cancer cells died during chemotherapy infusion.

Studies Find Merlin CP-GEP Test Improved Melanoma Risk Stratification

Dec 18, 2025 | Melanoma

Two peer-reviewed studies demonstrate superior risk stratification compared to traditional clinicopathologic features and competitor testing.

Roche Gains FDA Approval for Expanded HER2 Diagnostic Test Indications

Dec 15, 2025 | Breast

The test can now be used to identify HER2-positive metastatic breast cancer patients that could be eligible for Enhertu.

Test Validated to Predict Recurrence Risk and Radiation Therapy Benefit in Breast Cancer

Dec 12, 2025 | Breast

A blinded validation in more than 400 women shows the test provides clearer guidance on recurrence risk and radiation therapy decisions.

Cell-Free DNA Test May Identify Immunotherapy Adverse Events Earlier

Dec 12, 2025 | Cancer

Johns Hopkins researchers found the blood test detected multiorgan tissue damage in patients experiencing immune-related adverse events from checkpoint inhibitor therapy.